DT2216
Phase 2- Indications
- Fibrolamellar carcinoma, Platinum-resistant ovarian cancer, Peripheral T-cell lymphoma, Cutaneous T-cell lymphoma, T-cell lymphoma, Relapsed/refractory solid tumors, Relapsed/refractory hematologic malignancies
Company intelligence / Profile preview
Dialectic Capital
Dallas, Texas, United Statesdialectictherapeutics.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 2
01
Overview
Dialectic Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies using its proprietary targeted protein degradation platform. The company's lead candidate, DT2216, is a first-in-class BCL-XL proteolysis-targeting chimera (PROTAC) designed to selectively degrade BCL-XL, a protein that helps cancer cells survive and resist chemotherapy. By utilizing PROTAC technology, Dialectic aims to overcome the dose-limiting toxicities, such as thrombocytopenia, associated with traditional BCL-XL inhibitors. The company is currently evaluating its lead program in Phase 1 clinical trials for patients with relapsed or refractory solid tumors and hematologic malignancies.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeProteolysis-targeting chimera therapyPROTAC
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
University of FloridaUniversity of Texas Health Science Center at San Antonio
Beyond the preview
Go deeper on Dialectic Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dialectic Capital.